Final fall, Obagi Medical formally entered the injectable house with the launch of Saypha MagIQ, its FDA-approved hyaluronic acid filler for average to extreme nasolabial folds. The transfer marked a serious evolution for the skin-care large, placing it in direct competitors with established filler portfolios like RHA, Restylane and Juvéderm.
This week, the model expanded that portfolio once more. Obagi introduced FDA approval of Saypha ChIQ, a hyaluronic acid filler designed for cheek augmentation and correction of midface contour deficiencies in sufferers over 21. The brand new approval makes ChIQ the second injectable below Obagi’s rising aesthetics umbrella, additional signaling the model’s ambitions to grow to be a extra complete participant within the class.
Like MagIQ, ChIQ comes out of Obagi’s partnership with Austria-based Croma-Pharma, the worldwide aesthetics firm behind the Saypha filler line. Whereas the model could really feel newer to U.S. injectors, Croma has been within the injectable house for many years, with greater than 130 million syringes distributed throughout 80 international locations.
On the core of ChIQ is Croma’s MACRO Core Expertise, a specialised hyaluronic acid matrix designed for larger carry and structural help. The result’s a filler higher fitted to creating form, contour and projection within the cheeks and midface.
“The FDA approval of ChIQ is thrilling as a result of it fills an vital hole,” says Austin, TX oculoplastic surgeon Sheila Barbarino, MD. “It’s the next G-prime hyaluronic acid filler designed to offer enhanced structural help and carry. I’ve had nice success with Obagi’s present HA filler, MagIQ, which has grow to be a real workhorse in my follow because of its versatility, predictability and natural-looking outcomes. The addition of ChIQ expands the portfolio and provides suppliers and sufferers one other helpful possibility for these searching for larger definition, contour and longevity whereas sustaining a refined, pure aesthetic.”
With ChIQ, Obagi continues to develop past skincare, constructing out an injectable lineup that enhances the therapies many suppliers are already pairing with topical regimens. And in a crowded filler market, it offers injectors an alternative choice backed by a long time of world expertise.
